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Abstract
Background: The downstream of tyrosine kinase/docking protein (Dok) adaptor protein family has seven members, 
Dok1 to Dok7, that act as substrates of multiple receptor tyrosine kinase and non-receptor tyrosine kinase. The 
tropomyosin-related kinase (Trk) receptor family, which has three members (TrkA, TrkB and TrkC), are receptor tyrosine 
kinases that play pivotal roles in many stages of nervous system development, such as differentiation, migration, axon 
and dendrite projection and neuron patterning. Upon related neurotrophin growth factor stimulation, dimerisation 
and autophosphorylation of Trk receptors can occur, recruiting adaptor proteins to mediate signal transduction.
Results: In this report, by using yeast two-hybrid assays, glutathione S-transferase (GST) precipitation assays and 
coimmunoprecipitation (Co-IP) experiments, we demonstrate that Dok6 selectively binds to the NPQY motif of TrkC 
through its phosphotyrosine-binding (PTB) domain in a kinase activity-dependent manner. We further confirmed their 
interaction by coimmunoprecipitation and colocalisation in E18.5 mouse cortex neurons, which provided more in vivo 
evidence. Next, we demonstrated that Dok6 is involved in neurite outgrowth in mouse cortex neurons via the RNAi 
method. Knockdown of Dok6 decreased neurite outgrowth in cortical neurons upon neurotrophin 3 (NT-3) stimulation.
Conclusions: We conclude that Dok6 interacts with the NPQY motif of the TrkC receptor through its PTB domain in a 
kinase activity-dependent manner, and works as a novel substrate of the TrkC receptor involved in NT-3-mediated 
neurite outgrowth in mouse cortex neurons.
Background
P62Dok/Dok1, which was identified by Carpino et al. and
Yamanashi and Baltimore in 1997, was the first identified
member of the downstream of tyrosine kinase/docking
protein (Dok) family. Since then, six other members have
been identified: p56Dok/Dok2/DokR, Dok3/DokL, Dok4,
Dok5, Dok6/Dok5 like and Dok7 [1-4]. Dok family pro-
teins are adaptor proteins that act as substrates of multi-
ple receptor tyrosine kinases and non-receptor tyrosine
kinases [5,6]. All seven family members share a similar
structural topology: an N-terminal pleckstrin homology
(PH) domain, a central phosphotyrosine-binding (PTB)
domain, and a C-terminal region [4].
Interestingly, although all the members share almost
same structural feature, they exert different, even oppo-
site, roles in different tissues and organs. Dok1 to Dok3,
which are predominantly expressed in haematopoietic
tissues, act as negative regulators [7-12]. The results from
single or double knockout of Dok1/Dok2 mice provided
solid evidence to indicate their negative roles in leukemo-
genesis [11,13,14]. Yasuda et al. also showed that Dok1
and Dok2 are negative regulators of the T cell receptor
signal pathway [15]. Dok3 exerts its negative role in the
immunoreceptors of B cells and the macrophage signal-
ling pathway by formation of Dok3-SHIP1 complex
[1,16].
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The other four family members, Dok4 to Dok7, are
expressed in non-haematopoietic tissues, functioning in
different places and in different ways. Dok4 is widely
expressed, especially in intestine, kidney and lung that are
all epithelial in origin. Bedirian et al. showed that Dok4
may function as an inhibitor of the tyrosine kinase signal
pathway [17], while Grimm et al. found that Dok4 and
Dok5 enhanced c-Ret-dependent activation of mitogen-
activated protein kinase (MAPK) and promoted neurite
outgrowth in PC12 cells [2]. Also, Uchida et al. showed
that Dok4 may promote glial cell-derived neurotrophic
factor (GDNF)-mediated neurite outgrowth in TGW
cells through activation of the Rap1-Erk1/2 pathway [18].
Dok5 is mainly expressed in nervous system. It acts as a
substrate for the insulin receptor (IR) and GDNF receptor
c-Ret, and can promote GDNF-induced neurite out-
growth in PC12 cells [2,19]. For Dok6, in situ hybridisa-
tion results indicated that it is also specifically expressed
in the nervous system, especially in the cortex and dorsal
root ganglia (DRG). Crowder et al. showed that Dok6
could promote Ret-mediated neurite outgrowth in N2A-
α1 cells [3]. Dok7 was identified recently and plays an
important role in neuromuscular synaptogenesis by
interaction with muscle specific kinase (MuSK). Mice
lacking Dok7 fail to form acetylcholine receptor clusters
and neuromuscular synapses [4]. Patients who have
mutations in Dok7 develop congenital myasthenic syn-
drome (CMS) associated with small neuromuscular syn-
apses [20,21].
Our previous work has shown that Dok5 is a substrate
of tropomyosin-related kinase (Trk)B and TrkC receptors
and is involved in neurotrophin-induced MAPK activa-
tion [22]. Neurotrophins, including nerve growth factor
(NGF), brain-derived neurotrophic factor (BDNF), neu-
rotrophin 3 (NT-3) and neurotrophin 4/5 (NT-4/5), and
so on, are a family of growth factors implicated in several
different functions in the nervous system [23,24]. There
are two types of receptors for neurotrophins: the Trk
family are high affinity receptors, while p75 is a low affin-
ity receptor. The Trk family receptors have three mem-
bers, TrkA, TrkB and TrkC, that are structurally
conserved and exhibit specificity to different neurotro-
phins. TrkA is the preferred receptor for NGF, TrkB pre-
fers BDNF, while NT-3 is the preferred ligand of TrkC
[25]. Neurotrophins stimulation can induce the dimerisa-
tion and phosphorylation of Trk receptors, which then
recruit and phosphorylate downstream adaptor proteins
to mediate signal transduction [24-26]. It has been
reported that neurotrophins and Trk receptors are
involved in almost all stages of nervous system develop-
ment, such as survival, proliferation, differentiation,
migration, axon and dendrite projection, and neuron pat-
terning [23,27-30].
To date, Dok6's functions in the nervous system have
been poorly understood. In this study, we identified Dok6
as a novel substrate of the TrkC receptor. We confirmed
that Dok6 selectively binds to the NPQY motif of TrkC
through its PTB domain in a kinase activity-dependent
manner. Immunostaining results showed that TrkC and
Dok6 colocalise in E18.5 mouse cortical neurons. Knock-
down of Dok6 decreased neurite outgrowth in cortical
neurons upon NT-3 stimulation, which indicates that
Dok6 is involved in NT-3-mediated neuronal develop-
ment.
Results
Dok6 binds to the TrkC intracellular domain (ICD) but not 
TrkA or TrkB through the PTB domain in a yeast two-hybrid 
system
Our previous work indicated that Dok5, a member of the
p62Dok family , directly interacted with T rkB and T rkC
receptors to act as a downstream substrate to induce
MAPK activation [22]. We used DNAMAN software
(Lynnon Corporation, Pointe-Claire, Quebec, Canada
H9R 2A3) to analyse the homology of Dok family proteins
and found that Dok6 and Dok5 are the most conserved
among all seven family members (Figure 1a), which
means Dok6 may be more like Dok5 than any other mem-
bers in the family. In consideration of the same specific
neural expression pattern of Trk receptors and Dok6 in
embryonic mice [3], we hypothesised that Dok6 may bind
to Trk receptors directly to act as a downstream sub-
strate, as Dok5 does, and play a role in the embryonic
development. To verify this, we first used a yeast two-
hybrid system to test whether there were interactions
between Dok6 and Trk receptors. Interestingly, the
results showed that Dok6 only binds to the TrkC ICD, but
not to TrkA or TrkB, different to results with Dok5 (Fig-
ure 1b,c). The results implied more specificity of Dok6 to
Trk receptors compared with Dok5. We then inserted the
Dok6 PH domain, PTB domain and C-terminal region
into the pACT2 vector and tested for these by yeast two-
hybrid assay to determine the interaction region for
Dok6. As shown in Figure 1d, like Dok5, the PTB domain
of Dok6 is the key domain responsible for interaction;
neither the PH domain nor the C-terminal region is
involved in the interaction.
Dok6 binds to TrkC receptor in glutathione S-transferase 
(GST) precipitation and coimmunoprecipitation (Co-IP) 
assays
To confirm the results of the yeast two-hybrid assay, we
performed a GST precipitation assay. As shown in Figure
2a, upon neurotrophin stimulation, Trk receptors became
highly phosphorylated compared to those without stimu-
lation, as shown by blotting with anti-p-Trk antibodyLi et al. BMC Biology 2010, 8:86
http://www.biomedcentral.com/1741-7007/8/86
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(Figure 2a, panel 3). Consistent with results from the
yeast two-hybrid assay findings, the precipitation results
proved that the Dok6 PTB domain binds to the activated
TrkC receptor strongly in vitro, while no remarkable
binding was found between Dok6 and TrkA or TrkB with
activation or no activation (Figure 2a, panel 1). Next, by
Co-IP experiment, we further investigated the interaction
between Dok6 and activated TrkC receptor (Figure 2b).
The consistent results of the yeast two-hybrid assay, GST
precipitation assay and Co-IP experiment implied that
Dok6 selectively binds to TrkC receptor, but not TrkA or
TrkB.
Dok6 binds to the NPQY motif of TrkC receptor in a kinase 
activity-dependent manner and could be phosphorylated 
upon NT-3 stimulation
As shown in Figure 3a, there are five tyrosine residues
(Tyr516 Tyr705 Tyr709 Tyr710 Tyr820) in the TrkC
receptor ICD that could be phosphorylated upon treat-
ment of NT-3; each tyrosine residue mutation would dis-
rupt interaction between the receptor and corresponding
substrates [25,31]. Among them, Tyr516 is located in the
conserved NPQY motif, which is the typical binding
motif of the PTB domain [26,31,32]. As known from pre-
vious work, the PTB domain recognises the NPQY motif
in two different manners: dependent or independent on
phosphorylation. Our previous work demonstrated that
Dok5 binds to TrkB and TrkC directly at this site depend-
ing on the phosphorylation state. Therefore, we hypothe-
sised that this tyrosine residue was also important for the
interaction with Dok6. Another residue, Lys572, is essen-
tial for tyrosine kinase activity of TrkC. Mutation of this
site would produce a kinase-inactive TrkC receptor that
could be used to test whether this interaction is depen-
d e n t  o n  k i n a s e  a c t i v i t y  o r  n o t .  T o  t h i s  e n d ,  w e  c o n -
structed serial mutant TrkC receptors (including five
tyrosine residue mutants and one lysine mutant) for yeast
two-hybrid assay and GST precipitation experiments to
Figure 1 Downstream of tyrosine kinase/docking protein (Dok)6 binds to tropomyosin-related kinase (Trk)C intracellular domain (ICD) but 
not TrkA or TrkB through the phosphotyrosine-binding (PTB) domain in a yeast two-hybrid system. (a) Homology results of seven p62Dok 
family members analysed with DNAMAN software. (b) Schematic diagram showing the structures of the Dok6 and Trk receptors. (c) Dok6 interacts 
with the TrkC ICD, but not with TrkA ICD or TrkB ICD in a yeast two-hybrid system. Yeast (SFY526) were transformed with Trk ICD using a pAS2-1 vector 
and Dok6 using a pACT2 vector, and then cultured on SD/-Trp/-Leu plates for 4 days at 30°C. Colony lift β-galactosidase assays were performed ac-
cording to the user manual. (d) The Dok6 PTB domain, but not the pleckstrin homology (PH) domain or C-terminal region, binds to TrkC ICD in yeast 
two-hybrid assays.Li et al. BMC Biology 2010, 8:86
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Figure 2 Downstream of tyrosine kinase/docking protein (Dok)6 binds to tropomyosin-related kinase (Trk)C receptor in glutathione S-
transferase (GST) precipitation and coimmunoprecipitation (Co-IP) assays. (a) The Dok6 phosphotyrosine-binding (PTB) domain binds to the 
TrkC receptor in GST precipitation assays. Human embryonic kidney (HEK)293 cells were transfected with pcDNA3.1V5-Trks and treated with or with-
out neurotrophins (100 ng/ml) for 10 min. The cell lysates were incubated with Dok6-PTB-GST Sepharose 4B beads at 4°C for 2 h. The bound proteins 
were then analysed by western blotting with anti-V5 antibody (upper panel). Cell lysates were examined by anti-V5 or anti-pTyr antibodies to detect 
the expression and phosphorylation levels of Trk receptors (second and third panel). Dok6-PTB-GST proteins were tested by Coomassie Brilliant Blue 
staining (bottom panel). (b) Dok6 binds to the TrkC receptor in Co-IP assays. HEK293 cells were cotransfected with Flag-Dok6 and V5-TrkC. Before har-
vest, the cells were treated with or without 100 ng/ml NT3 for 10 min. Cell lysates were immunoprecipitated by anti-Flag and then were detected by 
western blotting with anti-V5 and anti-Flag.Li et al. BMC Biology 2010, 8:86
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determine the binding site on the TrkC receptor for Dok6
and to ascertain whether this binding depends on phos-
porylation or not.
As expected, the yeast two-hybrid results showed that
TrkC Y516F (M2) lost most interaction with Dok6, while
the other four tyrosine mutant receptors (M3-M6) did
not dramatically affect binding. The kinase-inactive
receptor TrkC K572A (M1) had no interaction with Dok6
either, which implied that the NPQY motif and the kinase
activity of TrkC receptor are both essential for this inter-
action (Figure 3b).
Using GST precipitation experiments, we further con-
firmed that Dok6 binds to the NPQY motif of the TrkC
receptor depending on phosphorylation. Wild-type TrkC
receptor could be precipitated by Dok6 upon NT-3 stim-
ulation, while neither the mutant receptor TrkC K572A
(M1) nor TrkC Y516F (M2) could interact with Dok6
(Figure 3c). Consistent with yeast two-hybrid data, the
unrelated tyrosine mutant TrkC Y820F (M6) showed sim-
ilar result as the wild-type TrkC receptor. Moreover, as a
substrate of TrkC, the phosphorylation level of Dok6 was
greatly enhanced upon treatment with NT-3 (Figure 3d).
In summary, the PTB domain of Dok6 binds to Tyr516 in
t h e  c o n s e rv e d  N P Q Y  m o t i f  o f  t h e  T r k C  r e c e p t o r  i n  a
kinase activity-dependent manner.
Dok6 colocalises with TrkC and binds to TrkC receptor in 
E18.5 mouse brains
As we had confirmed that Dok6 could interact with the
TrkC receptor in vitro, next we investigated if Dok6 could
Figure 3 Downstream of tyrosine kinase/docking protein (Dok)6 binds to the NPQY motif of tropomyosin-related kinase (Trk)C in a kinase-
activity-dependent manner and was phosphorylated on neurotrophin 3 (NT-3) stimulation. (a) Alignment of amino acid sequences around 
the NPQY motif of Trk family receptors (homology level: red, 100%; green, ≥50%), and schematic diagram showing the important amino acids of TrkC. 
(b) Mutation analysis of the key amino acids in the TrkC receptor for Dok6 binding. A yeast two-hybrid assay was performed with pACT2-Dok6-phos-
photyrosine-binding (PTB) and TrkC intracellular domain (ICD) mutants using the pAS2-1 vector, including CM1(K572A), CM2(Y516F), CM3(Y705A), 
CM4(Y709D), CM5(Y710E), CM6(Y820F). (c) Dok6 binds to the NPQY motif of the TrkC receptor in a kinase activity-dependent manner in glutathione 
S-transferase (GST) precipitation assays. Human embryonic kidney (HEK)293 cells were transfected with wild-type TrkC, CM1, CM2 and CM6. After stim-
ulation with NT-3, cell lysates were collected for GST precipitation assays. (d) Dok6 is phosphorylated by the TrkC receptor, which is activated upon 
NT-3 stimulation. HEK293 cells were cotransfected with V5-TrkC and Flag-Dok6, and cells were treated with/without NT-3 before harvest. Cell lysates 
were then analysed by western blotting with anti-pTyr antibody.Li et al. BMC Biology 2010, 8:86
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bind to the TrkC receptor in vivo. To test TrkC and Dok6
commercial antibodies, we overexpressed V5-tagged
TrkC and Flag-tagged Dok6 in human embryonic kidney
(HEK)293 cells, and tested HEK293 cell lysates and E18.5
mouse brain lysates via western blot. As shown in Figure
4a, TrkC and Dok6 that was either endogenously
expressed in E18.5 mouse brains or overexpressed in
HEK293 cells (V5-TrkC, Flag-Dok6) were both recogn-
ised by these antibodies; the anti-V5 and anti-Flag anti-
bodies were used as positive control (Figure 4a, panels 1
and 2). Additionally, to verify the specificity of the TrkC
antibody, we overexpressed V5-tagged TrkA, TrkB and
TrkC in HEK293 cells, and cell lysates were blotted with
anti-V5 or anti-TrkC antibodies. The results showed that
our anti-TrkC antibody only recognised the TrkC recep-
tor, but not the TrkA or TrkB receptors (Figure 4a, panels
3 and 4).
As has been shown previously the expression levels of
TrkC and Dok6 in embryonic mouse cortex are remark-
able [2,3,28,30,33], so we hypothesised that Dok6 may
work as a substrate of the TrkC receptor and play a role in
embryonic mouse cortex development. Immunostaining
showed that TrkC and Dok6 colocalise at the membrane,
cytoplasm and neurites in primary cultured cortex neu-
rons (Figure 4b). We then collected homogenates of E18.5
mouse brains to perform immunoprecipitation tests with
anti-Dok6, using IgG as a negative control. The results
showed that the TrkC receptor was immunoprecipitated
by anti-Dok6 antibody remarkably well, but not by IgG
(Figure 4c, left panel). Also, consistent with results
achieved by in vitro experiments, both TrkC and Dok6
are phosphorylated (Figure 4c, right panel). Taken
together, these results provided evidence that Dok6
works as a substrate of the TrkC receptor in vivo and may
have important roles in cortical neurons.
Dok6 plays a role in neurite outgrowth in E18.5 mouse 
primary cortex neurons
T o study the exact roles of Dok6 in the cortex, we con-
structed knockdown clones of Dok6 (Dok6i) and non-
sense controls (details are given in the Methods section).
First, we tested the inhibition effect of our knockdown
constructs by using western blotting. As shown in Figure
5a, Dok6i decreased the expression level of Dok6 almost
threefold in HEK293 cells compared to the nonsense con-
trol construct.
Figure 4 Downstream of tyrosine kinase/docking protein (Dok)6 colocalises with tropomyosin-related kinase (Trk)C and binds to TrkC re-
ceptor in E18.5 mouse brains. (a) Specificity tests for TrkC (R&D Systems) and Dok6 (Abcam) antibodies. Human embryonic kidney (HEK)293 cells 
were transfected with V5-TrkC and Flag-Dok6 separately. Cell lysates and homogenates of E18.5 mouse brains were then detected by western blotting 
with anti-TrkC and anti-Dok6 antibodies separately, using anti-V5 and anti-Flag antibodies as positive controls (panels 1 and 2). HEK293 cells were 
transfected with V5-TrkA, V5-TrkB and V5-TrkC separately. Cell lysates were then detected by western blotting with anti-TrkC and anti-V5 antibodies 
(panels 3 and 4). (b) TrkC colocalises with Dok6 in E18.5 mouse primary cortex cells. Immunostaining in cortex cells with anti-TrkC and anti-Dok6 an-
tibodies. Cells were counterstained with 4',6-diamidino-2-phenylindole (DAPI) to show nuclei. Scale bar: 10 μm. (c) Dok6 binds to the TrkC receptor in 
mouse brain. Homogenates of E18.5 mouse brains were immunoprecipitated with anti-Dok6 and IgG antibodies; the bound proteins were then anal-
ysed by western blotting with anti-TrkC, anti-Dok6 and anti-pTyr antibodies.Li et al. BMC Biology 2010, 8:86
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Figure 5 Downstream of tyrosine kinase/docking protein (Dok)6 plays a role in neurite outgrowth in E18.5 mouse cortex primary neurons. 
(a) Knockdown efficiency tests of Dok6i construct and nonsense control construct. Human embryonic kidney (HEK)293 cells were cotransfected with 
Flag-Dok6 and Dok6i or Flag-Dok6 and nonsense control constructs separately. The cell lysates were then analysed by western blotting with anti-Flag 
antibody. (b) E18.5 mouse cortex primary cells were transfected with Dok6i and nonsense control constructs, both of which were green fluorescence 
positive in cells. An immunofluorescence test was performed 48 h later with anti-microtubule-associated protein 2 (MAP2; red). and photographs of 
cells that were positive for both red and green fluorescence were taken (white arrow). Scale bars: panel a 50 μm, panel b 200 μm, panel c-h 30 μm. (c) 
Quantification of neurite outgrowth in cortex neurons. In all, 10 random fields of cells from each experimental group were photographed. Neurite 
length was quantified by measuring the longest neurite processes of cells that were positive for both green and red fluorescence by using NIS-Ele-
ments software. *P value < 0.05 by Student t test.Li et al. BMC Biology 2010, 8:86
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Crewder et al. showed that Dok6 could promote neu-
r i t e  o u t g r o w t h  i n  N 2 A  c e l l s  [ 2 , 3 ] ,  s o  w e  h y p o t h e s i s e d
whether Dok6 was also involved in neurite outgrowth in
cortical neurons; this was tested for by knockdown of the
expression of Dok6. We transfected primary cultured
cortex cells (E18.5 ICR mouse) with Dok6i and nonsense
control. As the RNAi vector had a green fluorescent pro-
tein (GFP) expression cassette within it, the cells with
green fluorescence were therefore transfected cells;
microtubule-associated protein 2 (MAP2; red) was used
as a marker for neurons. Then, 48 h later, the lengths of
neurites in cells with both red and green fluorescence
(Figure 5b) were measured. The results showed that
knockdown of Dok6 caused an almost 25% decrease in
neurite outgrowth in primary cortex neurons compared
to nonsense control (Figure 5c), which indicated that
Dok6 plays a role in neurite outgrowth in cortical neu-
rons.
Dok6 is involved in cortex neuron neurite outgrowth 
through the NT-3/TrkC pathway
As we have shown that Dok6 works as a substrate of the
TrkC receptor in mouse brain, next we investigated
whether Dok6 exerted its role in cortex neuron neurite
outgrowth through the NT-3/TrkC pathway. First, we
performed Co-IP experiments to test for interactions
between TrkC and Dok6 in cortex neurons that were
treated with or without NT-3. Consistent with previous
results, Dok6 binds to the TrkC receptor in cortex neu-
rons upon NT-3 stimulation, while without NT-3 stimu-
lation no obvious interactions exist (Figure 6a). Next, we
transfected cortex cells with Dok6i and the nonsense con-
trol construct. Then, 12 h later, these cells were treated
with or without 100 ng/ml NT-3. The neurite lengths of
transfected cells were measured as described above (Fig-
ure 6b). The results showed that the average neurite
length for positive neurons increased almost six fold after
stimulation with NT-3 in the nonsense control group.
However, in the Dok6 knockdown group, the increase
was only about 3.5-fold (Figure 6c). This result suggests
that NT-3 promotes neurite outgrowth in the cortical
neuron, and knockdown of Dok6 partially blocks the NT-
3 promotion effect in neurite outgrowth, which implies
that Dok6 is ex erting its role in corte x neuron neurite
outgrowth through the NT-3/TrkC pathway.
Discussion
In the present work we used yeast two-hybrid assays,
GST precipitation assays and Co-IP experiments to dem-
onstrate that Dok6 interacts with TrkC, which is a mem-
ber of Trk receptors family. We also ascertained that
Dok6 binds to the NPQY motif in the ICD of TrkC
through its PTB domain, and this interaction depends on
TrkC receptor kinase activity induced by NT-3. Our pre-
vious study showed that Dok5 could interact with TrkB
and TrkC, but not with TrkA [22]. Although the homol-
ogy between the Dok5 and Dok6 PTB domains is as high
as 76.47%, there are still some different amino acids,
which may result in the different protein structures. This
may be why Dok5 and Dok6 exhibit different binding
specificities to Trk receptor members. Additionally, the
structural differences in Trk receptor members may be
the reason why Dok6 only binds to TrkC, and not to TrkA
or TrkB. Trk receptors play pivotal roles in almost all
aspects of nervous system development, and knockout
results for each member or its ligand indicate that TkrA,
TrkB and TrkC play different roles in these events
[24,25,27,28,34]. Dok6 selectively binding to the TrkC
receptor may suggest its physiological function in the
NT-3/TrkC pathway, while Dok5 may be involved in both
the BDNF/TrkB and NT-3/TrkC pathways simultane-
ously.
It has been reported that many adaptor proteins may
bind to the NPQY motif in Trk receptor ICDs through
the PTB domain, such as Shc, insulin receptor substrate
(IRS) and fibroblast growth factor receptor substrate 2
(FRS2) [35,36]. Trk receptors recruit these adaptor pro-
teins to perform their pivotal roles. For example, upon
stimulation with NGF, TrkA recruits Shc and phospholi-
pase C (PLC)-γ1 to promote neurite outgrowth in PC12
cells [26]. Considering the complexity of the signal trans-
duction network, it is hard to draw a picture of how these
proteins could work together properly. In general, each
single receptor could bind to several adaptor proteins;
meanwhile, each adaptor protein could also interact with
different kinds of receptor. Therefore, it is possible that,
by using different receptor-adaptor combinations, cells
can finely tune their signal transduction networks to fulfil
different tasks. Also, we must consider the distinct
expression patterns (time and space) of these receptors
and adaptor proteins to study their exact roles in vivo. As
reported by Crowder et al., Dok6 is mainly expressed in
the embryonic brain and adult central nervous system,
especially in the cortex and DRG [3]. This suggests that
Dok6 may have a role in brain development. Additionally,
t h e  NT - 3 / T r k C  p a t h w a y  i s  b e l i e v e d  t o  r e g u l a t e  n e u r a l
precursor cell differentiation during cortical development
[30]. The overlapping expression patterns of TrkC and
Dok6 in the cortex imply their functional relevance on a
physiological level. Furthermore, in this study our immu-
noprecipitation experiment and colocalisation test results
confirmed that Dok6 interacts with TrkC in mouse cor-
tex; this provided more evidence of Dok6's real function
in vivo.
We also demonstrated that Dok6 is involved in NT-3-
mediated neurite outgrowth of mouse cortex neurons,
which indicates that Dok6 plays important roles in corti-
cal development. These results enriched the signal trans-Li et al. BMC Biology 2010, 8:86
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duction networks of the NT-3/TrkC pathway in the
cortex. However, the downstream targets and signal path-
way of Dok6 are poorly understood [2,3,19], and identifi-
cation of these downstream targets is necessary for
further studies. Like Dok1 to Dok5, several tyrosine resi-
dues localise in the C-termini of Dok6, which may serve
as binding sites for downstream targets and hence may be
critical for downstream signal transduction. However,
although Dok5 and Dok6 share high homology with
Dok1-Dok4, they fail to interact with adaptors such as
Ras GTPase activating protein (RasGAP), Nck, and Src
homology 2 domain-containing inositol phosphatase
(SHIP), and so on, and bioinformatics studies have not
clarified why this is the case [3,19]. It may be that immu-
noprecipitation, coupled with mass spectrometry identi-
fication assays, would be a good choice to elucidate the
downstream targets. However, genetic study of Dok6
knockout mice may provide the strongest evidence for its
physiological function in vivo.
Figure 6 Downstream of tyrosine kinase/docking protein (Dok)6 is involved in cortex neuron neurite outgrowth through the neurotrophin 
3 (NT-3)/tropomyosin-related kinase (Trk)C pathway. (a) Dok6 binds to the TrkC receptor in cortical neurons upon NT-3 stimulation. E18.5 mouse 
cortex neurons were cultured in empty DMEM for 24 h, then treated with or without 100 ng/ml NT-3 for 10 min. Cell lysates were immunoprecipitated 
by anti-Dok6 and were then detected by western blotting with anti-TrkC and anti-Dok6. (b) E18.5 mouse cortex primary cells were transfected with 
Dok6i and nonsense control constructs (green) separately; 12 h later, cultured cells were transferred into DMEM with/without 100 ng/ml NT-3 for an-
other 72 h. Then immunofluorescence was performed with anti-microtubule-associated protein 2 (MAP2; red) and photographs of cells that were 
positive for both red and green fluorescence (white arrow) were taken. Panels a and b show the nonsense control group treated without or with 100 
ng/ml NT-3; panels c and d show the Dok6i group treated without or with 100 ng/ml NT-3. Scale bars for panels a, c and d are 100 μm, panel b is 200 
μm, and panels e-p are 30 μm. (c) Quantification of neurite outgrowth in cortex neurons. A total of 10 random fields of cells from each experimental 
group were photographed. Neurite length was quantified by measuring the longest neurite processes of cells that were positive for both green and 
red fluorescence by using NIS-Elements software. *P value < 0.05 by Student t test.Li et al. BMC Biology 2010, 8:86
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Conclusions
In summary, we have identified Dok6 as a new substrate
of the TrkC receptor and Dok6 selectively binds to the
NPQY motif of TrkC through its PTB domain in a kinase
activity-dependent manner. We have also shown that
Dok6, as a substrate of TrkC, plays an important role in
NT-3-mediated neurite outgrowth in mouse cortex neu-
rons. These results give new clues as to Dok6's function
in vivo, and enriched the NT-3/TrkC pathway networks
in cortical development. It also shed light on the treat-
ment of nervous system deficiency diseases.
Methods
Antibodies and reagents
Antibodies used were: mouse anti-V5 monoclonal anti-
body (mAb) (Invitrogen USA), mouse anti-Flag mAb
(Sigma USA), mouse anti-pTyr (PY99) mAb (Santa Cruz
USA), goat anti-TrkC pAb (R&D Systems USA), rabbit
anti-Dok6 polyclonal antibody (pAb) (Abcam England),
mouse anti-MAP2 mAb (Abcam England). Human
recombinant NT-3 was product of Peprotech Inc.
Polylysine was purchased from Sigma.
Plasmid construction
The human trkA, trkB, trkC and dok6 full-length cDNA
were amplified from human foetal brain cDNA library.
For the yeast two-hybrid assay, the trk  receptor ICDs
were cloned into the pAS2-1 vector, while the whole dok6
cDNA or sequences coding for the PH domain, PTB
domain and C-terminal region were cloned into pACT2
vectors. The entire mutant constructs for the trkC recep-
tor, including trkC K572A (M1), trkC Y516F (M2), trkC
Y705A (M3), trkC Y709D (M4), trkC Y710E (M5) and
trkC Y820F (M6) were generated by using a QuickChange
Site-Directed Mutagenesis Kit (Stratagene).
For prokaryotic expression, the sequence coding for the
dok6 PTB domain was cloned into the pGEX6P-1 vector.
For eukaryotic expression, wild-type and mutant trkC
receptors were cloned into the pcDNA3.1-V5 vector,
while Dok6 was cloned into the pcDNA3.1-Flag vector.
For knockdown of Dok6, the Dok6i sequence (5'-
GCACGAAAGATTAATGCTAGAT-3') and nonsense
control sequence (5'-TTCTCCGAACGTGTCACGT-3')
were constructed into the small hairpin (shRNA) vector
pGPU6/GFP/Neo, which was purchased from Shanghai
GenePharma.
Cell culture and transfection
HEK 293 cells were maintained in Dulbecco's modified
Eagle medium (DMEM) with 10% foetal bovine serum
(Hyclone) and transfected using Lipofectamine 2000
(Invitrogen). E18.5 mouse cortex primary cells were cul-
tured in Neurobasal-A medium (Gibco) with B27
(Gibco). All cells were maintained in a humidified atmo-
sphere containing 5% CO2. For immunofluorescence, pri-
mary cortex cells were plated onto glass cover slips coated
with 100 μg/ml polylysine, then transfected using Lipo-
fectamine 2000 (Invitrogen).
Yeast two-hybrid assay
Trk receptor ICDs were fused into the GAL4 DNA bind-
ing domain in the pAS2-1 vector. The wild-type dok6 or
dok6  PH domain, PTB domain and C-terminal region
were fused into the GAL4 activation domain in the
pACT2 vector. The cotransformation was performed in
yeast strain SFY526 by using the TE/LiAc (1 × TE/LiAC
made fresh from stocks of 10 × TE [0.1 M Tris-HCI, 0.01
M EDTA, pH 7.5] and 10× LiAC [1 M lithium acetate
adjusted to pH 7.5 with dilute acetic acid]) method
according to the user manual for the MATCHMAKER
yeast two-hybrid system 2 (Clontech USA). Transformed
yeasts were selected on SD dropout medium/-Leu/-Trp
plates at 30°C for 4 days. Then, colony lift β-galactosidase
assays were performed.
GST precipitation assay
The BL21 Escherichia coli strain was transformed with
the pGEX6P-Dok6-PTB plasmid, then the overnight cul-
ture diluted 1:500 into 200 ml LB medium and shaken at
37°C until an OD600 value of 0.6 was reached. The induc-
tion was performed by shaking at 30°C for 4 h with 0.8
mM isopropyl-β-D-thiogalactopyranoside. The purified
GST-Dok6-PTB fusion proteins were immobilised on
Sepharose 4B beads according to the manufacturer's pro-
tocol (Amersham Biosciences). The HEK293 cells, which
were transfected with serial pcDNA3.1-V5-Trk plasmids
for 24 h, were treated with or without neurotrophin for
10 min. Cell lysates were centrifuged and then the super-
natants were incubated with same amount of GST-Dok6-
PTB Sepharose 4B beads at 4°C for 2 h. The beads were
washed with 1 × phosphate-buffered saline (PBS) three
times and then resuspended with 1 × SDS loading buffer.
The denatured protein samples were analysed by western
blotting and Coomassie Brilliant Blue staining.
Co-IP assay
HEK293 cells were transfected into a six-well plate 1 day
prior to assay and cultured to 90% density. Then, cotrans-
fection was performed with pcDNA3.1-V5-TrkC and
pcDNA3.1-Flag-Dok6 and 24 h later the cells were stimu-
lated or not with 100 ng/ml NT-3 for 10 min. Then, cells
were lysed with 750 μl lysis buffer and immunoprecipita-
tion was performed as described previously [22].
Immunoprecipitation
Animal care and experimental procedures conformed to
Experimental Animal Regulations (China Science and
Technology Commission Order no. 2) and were approvedLi et al. BMC Biology 2010, 8:86
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by the Institutional Animal Care and Use Committee at
the Institute of Basic Medical Sciences, Chinese Academy
of Medical Sciences and Peking Union Medical College.
Homogenates of E18.5 ICR mouse brains were incubated
with rabbit IgG (Zhongshan Goldenbridge Biotechnology
Co., Ltd, Beijing, China) for 3 h at 4°C and then with pro-
tein A-agarose (Roche) overnight at 4°C. The next day,
these homogenates were centrifuged at 1,000 g and the
supernatants incubated with anti-Dok6 or IgG for 4 h at
4°C, followed by incubation with protein A-agarose for
another 4 h at 4°C. Then, the samples were washed with
PBS three times and resuspended with 1 × SDS loading
buffer. The denatured protein samples were then analy-
sed by western blotting with anti-TrkC and anti-Dok6.
Immunofluorescence microscopy
E18.5 ICR mouse cortex primary cells were isolated and
cultured as reported previously [37]. The cells were fixed
in 4% paraformaldehyde for 15 min, followed by washes
with PBS, and these cells were then permeabilised and
blocked with PBS containing 0.1% Triton and 5% rabbit
serum for 1 h. The cells were then incubated with pri-
mary antibodies diluted in blocking buffer overnight at
4°C, followed by incubation with secondary antibody for
2 h. After staining with 4',6-diamidino-2-phenylindole
(DAPI), cover slips were mounted with mounting
medium (Zhongshan Goldenbridge Biotechnology) and
analysed using confocal microscopy.
Neurite outgrowth assay
First, immunofluorescence (anti-MAP2, red fluores-
cence) was performed in E18.5 ICR mouse cortex pri-
mary cells transfected with knockdown constructs. Then,
to measure neurite outgrowth, 10 random fields of cells
from each experimental group were photographed. Neu-
rite length was quantified by measuring the longest neu-
rite process of cells that were positive with both green
and red fluorescence by using NIS-Elements software
(Nikon, 1300 Walt Whitman Road, Melville, N.Y. 11747-
3064, USA)
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